Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant

• Ernest H Law,
• Chris Cameron

Affiliations

Ernest H Law

ORCiD

Director, Value & Evidence, Pfizer, New York, NY 10017, USA

Chris Cameron

ORCiD

Chief Scientific Officer, Global Value & Evidence, EVERSANA, Sydney, Nova Scotia, B1P 1C6, Canada